{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T13:31:01Z","timestamp":1777555861151,"version":"3.51.4"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009192","name":"Alberta Innovates","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009192","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010090","name":"Women and Children's Health Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.ejpb.2018.06.018","type":"journal-article","created":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T19:57:15Z","timestamp":1529351835000},"page":"66-70","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["siRNA\/lipopolymer nanoparticles to arrest growth of chronic myeloid leukemia cells in vitro and in vivo"],"prefix":"10.1016","volume":"130","author":[{"given":"Juliana","family":"Valencia-Serna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamidreza M.","family":"Aliabadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Manfrin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahsa","family":"Mohseni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8974-7340","authenticated-orcid":false,"given":"Xiaoyan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1118-4170","authenticated-orcid":false,"given":"Hasan","family":"Uludag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2018.06.018_b0005","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc3317","article-title":"Pushing the limits of targeted therapy in chronic myeloid leukaemia","volume":"12","author":"O'Hare","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejpb.2018.06.018_b0010","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/ajh.23691","article-title":"Chronic myeloid leukemia 2014 update on diagnosis, monitoring, and management","volume":"89","author":"Jabbour","year":"2014","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ejpb.2018.06.018_b0015","doi-asserted-by":"crossref","first-page":"6429","DOI":"10.1016\/j.biomaterials.2013.04.060","article-title":"A review of the current status of siRNA nanomedicines in the treatment of cancer","volume":"34","author":"Resnier","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2018.06.018_b0020","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1038\/mtna.2015.13","article-title":"Progress in RNAi-mediated molecular therapy of acute and chronic myeloid leukemia","volume":"4","author":"Landry","year":"2015","journal-title":"Mol. Ther. Nucleic. Acids"},{"key":"10.1016\/j.ejpb.2018.06.018_b0025","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.2217\/nnm.16.32","article-title":"Fibronectin-modified surfaces for evaluating the influence of cell adhesion on sensitivity of leukemic cells to siRNA nanoparticles","volume":"11","author":"Valencia-Serna","year":"2016","journal-title":"Nanomedicine"},{"key":"10.1016\/j.ejpb.2018.06.018_b0030","doi-asserted-by":"crossref","first-page":"e44197","DOI":"10.1371\/journal.pone.0044197","article-title":"Effective non-viral delivery of siRNA to acute myeloid leukemia cells with lipid-substituted polyethylenimines","volume":"7","author":"Landry","year":"2012","journal-title":"Plos One"},{"key":"10.1016\/j.ejpb.2018.06.018_b0035","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.leukres.2014.08.008","article-title":"Polymeric nanoparticle-mediated silencing of CD44 receptor in CD34+ acute myeloid leukemia cells","volume":"38","author":"G\u00fcl-Uluda\u011f","year":"2014","journal-title":"Leuk. Res."},{"key":"10.1016\/j.ejpb.2018.06.018_b0040","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1084\/jem.20072316","article-title":"AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem\/progenitor cells","volume":"205","author":"Zhou","year":"2008","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejpb.2018.06.018_b0045","first-page":"375","article-title":"SKI-606, a 4-Anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice","volume":"63","author":"Golas","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejpb.2018.06.018_b0050","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jconrel.2013.05.014","article-title":"Investigating siRNA delivery to chronic myeloid leukemia K562 cells with lipophilic polymers for therapeutic BCR-ABL down-regulation","volume":"172","author":"Valencia-Serna","year":"2013","journal-title":"J. Cont. Release"},{"key":"10.1016\/j.ejpb.2018.06.018_b0055","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/ijc.31079","article-title":"Novel targets for sensitizing breast cancer cells to TRAIL-induced apoptosis with siRNA delivery","volume":"142","author":"Thapa","year":"2018","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejpb.2018.06.018_b0060","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0168-3659(03)00076-2","article-title":"Low-molecular-weight polyethylenimine as a non-viral vector for DNA delivery: comparison of physicochemical properties, transfection efficiency and in vivo distribution with high-molecular-weight polyethylenimine","volume":"89","author":"Kunath","year":"2003","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.ejpb.2018.06.018_b0065","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ejpb.2004.11.011","article-title":"Polyethylenimine-based non-viral gene delivery systems","volume":"60","author":"Lungwitz","year":"2005","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2018.06.018_b0070","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1002\/jgm.507","article-title":"Gene transfer with modified polyethylenimines","volume":"6","author":"Kichler","year":"2004","journal-title":"J. Gene. Med."},{"key":"10.1016\/j.ejpb.2018.06.018_b0075","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/jgm.228","article-title":"Polyethyleneimine-based immunopolyplex for targeted gene transfer in human lymphoma cell lines","volume":"4","author":"Guillem","year":"2002","journal-title":"J. Gene Med."},{"key":"10.1016\/j.ejpb.2018.06.018_b0080","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1021\/bc0256087","article-title":"Novel shielded transferrin-polyethylene glycol-polyethylenimine\/DNA complexes for systemic tumor-targeted gene transfer","volume":"14","author":"Kursa","year":"2003","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejpb.2018.06.018_b0085","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1021\/acs.molpharmaceut.6b01150","article-title":"Antibody-targeted cyclodextrin-based nanoparticles for siRNA delivery in the treatment of acute myeloid leukemia: physicochemical characteristics, in vitromechanistic studies, and ex vivopatient derived therapeutic efficacy","volume":"14","author":"Guo","year":"2017","journal-title":"Mol. Pharmaceutics."},{"key":"10.1016\/j.ejpb.2018.06.018_b0090","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1038\/sj.onc.1205653","article-title":"Killing of leukemic cells with a BCR\/ABL fusion gene by RNA interference (RNAi)","volume":"21","author":"Wilda","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.ejpb.2018.06.018_b0095","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.febslet.2004.06.048","article-title":"Suppression of bcr-abl synthesis by siRNAs or tyrosine kinase activity by Glivec alters different oncogenes, apoptotic\/antiapoptotic genes and cell proliferation factors (microarray study)","volume":"570","author":"Zhelev","year":"2004","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejpb.2018.06.018_b0100","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jconrel.2010.04.011","article-title":"Delivery of therapeutic shRNA and siRNA by Tat fusion peptide targeting BCR-ABL fusion gene in chronic myeloid leukemia cells","volume":"145","author":"Arthanari","year":"2010","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.ejpb.2018.06.018_b0105","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1021\/bc9004365","article-title":"Transferrin receptor-targeted liposomes encapsulating anti-BCR-ABL siRNA or asODN for chronic myeloid leukemia treatment","volume":"21","author":"Mendon\u00e7a","year":"2010","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejpb.2018.06.018_b0110","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.actbio.2015.07.032","article-title":"Stealth monoolein-based nanocarriers for delivery of siRNA to cancer cells","volume":"25","author":"Oliveira","year":"2015","journal-title":"Acta Biomaterialia"},{"key":"10.1016\/j.ejpb.2018.06.018_b0115","doi-asserted-by":"crossref","first-page":"9405","DOI":"10.1039\/C6NR00996D","article-title":"Biodegradable charged polyester-based vectors (BCPVs) as an efficient non-viral transfection nanoagent for gene knockdown of the BCR\u2013ABL hybrid oncogene in a human chronic myeloid leukemia cell line","volume":"8","author":"Yang","year":"2016","journal-title":"Nanoscale"},{"key":"10.1016\/j.ejpb.2018.06.018_b0120","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jconrel.2013.08.012","article-title":"Effective response of doxorubicin-sensitive and -resistant breast cancer cells to combinational siRNA therapy","volume":"172","author":"Aliabadi","year":"2013","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.ejpb.2018.06.018_b0125","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1007\/s11095-009-9864-8","article-title":"Transferrin receptor targeted lipopolyplexes for delivery of antisense oligonucleotide G3139 in a murine K562 Xenograft Model","volume":"26","author":"Zhang","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2018.06.018_b0130","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11899-016-0309-2","article-title":"Long-term side effects of tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"11","author":"Caldemeyer","year":"2016","journal-title":"Curr. Hematol. Malig. Rep."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641118305113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641118305113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:31:45Z","timestamp":1760545905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641118305113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":26,"alternative-id":["S0939641118305113"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2018.06.018","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"siRNA\/lipopolymer nanoparticles to arrest growth of chronic myeloid leukemia cells in vitro and in vivo","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2018.06.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}